Serum lactate levels as a marker of clinical severity in malaria: a prospective observational study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20262621Keywords:
Malaria, Serum lactate, Severe malaria, Hyperlactatemia, PrognosisAbstract
Background: Malaria remains a major cause of morbidity and mortality in tropical countries. Severe malaria is associated with microcirculatory dysfunction, tissue hypoxia, and metabolic derangements. Serum lactate may serve as an early marker of disease severity and prognosis. Objectives were to evaluate serum lactate levels in patients with malaria and assess their association with disease severity and clinical outcomes.
Methods: This prospective observational study included 100 adult patients with laboratory-confirmed malaria admitted to a tertiary care hospital. Clinical evaluation and laboratory investigations, including serum lactate estimation at admission, were performed. Disease severity was classified according to WHO criteria. Clinical outcomes were categorized as favorable or adverse.
Results: Of the 100 patients, 48% had Plasmodium vivax infection, 42% had Plasmodium falciparum infection, and 10% had mixed infection. Patients with severe malaria had significantly higher serum lactate levels than those with uncomplicated malaria (4.5±1.2 vs. 1.6±0.4 mmol/l; p<0.001). Elevated lactate levels were associated with hypotension, severe anemia, metabolic acidosis, renal dysfunction, altered sensorium, hepatic dysfunction, thrombocytopenia, and hypoglycemia. Adverse outcomes occurred in 45% of patients, including ICU admission (22%), prolonged hospital stay (18%), and mortality (8%). Serum lactate levels were significantly higher in patients with adverse outcomes than in those with favorable outcomes (4.5±1.2 vs. 1.6±0.4 mmol/L; p<0.001).
Conclusions: Serum lactate is significantly associated with disease severity and adverse clinical outcomes in malaria. Early lactate estimation may help identify high-risk patients and guide timely management.
References
World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization. 2015.
World Health Organization. WHO guidelines for malaria. Geneva: World Health Organization. 2021.
World Health Organization. Malaria fact sheet. Geneva: World Health Organization. 2023.
Day NPJ, Phu NH, Mai NTH, Chau TT, Loc PP, Chuong LV, et al. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med. 2000;28(6):1833-40.
Krishna S, Waller DW, ter Kuile F, Kwiatkowski D, Crawley J, Craddock CF, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg. 1994;88(1):67-73.
English M, Waruiru C, Amukoye E, Murphy S, Crawley J, Mwangi I, et al. Deep breathing in children with severe malaria: indicator of metabolic acidosis and poor outcome. QJM. 1997;90(9):563-9.
Hanson J, Lam SWK, Mahanta KC, Rajayabardhan P, Shamsul A, Sanjib M, et al. Relative contributions of macrovascular and microvascular dysfunction to disease severity in falciparum malaria. Clin Infect Dis. 2010;51(7):e61-8.
Plewes K, Leopold SJ, Kingston HWF. Pathophysiology, clinical presentation, and treatment of coma and acute kidney injury complicating falciparum malaria. Curr Opin Infect Dis. 2018;31(5):403-12.
van Genderen PJJ, Hesselink DA, Bezemer JM. Severe falciparum malaria in travellers: treatment, outcome and prognostic factors. J Travel Med. 2005;12(4):204-12.
Pössmeier P, Phu NH, Dondorp AM. Factors associated with hyperlactatemia in severe falciparum malaria. PLoS Pathog. 2021;17(6):e1009580.
De Backer D, Creteur J, Silva E, Jean-Louis V. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock. Intensive Care Med. 2003;29(6):905-12.
Nichol AD, Egi M, Pettila V, Rinaldo B, Craig F, Graeme H, et al. Relative hyperlactatemia and hospital mortality in critically ill patients: a retrospective multicentre study. Crit Care. 2010;14(1):R25.
Yusuf MA, Chowdhury AA, Bhuiyan MSI. Severe malaria: clinical spectrum and outcome in a tertiary care hospital. Infect Drug Resist. 2017;10:195-200.
National Vector Borne Disease Control Programme (NVBDCP). National framework for malaria elimination in India (2016-2030). New Delhi: Ministry of Health and Family Welfare, Government of India. 2016.
Dondorp AM, Fanello CI, Hendriksen ICE, Ermelinda G, Amir S, Kajal DC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647-57.
Downloads
Published
How to Cite
Issue
Section
